The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     
9 pts

Opinion on  Biogen Idec Inc (BIIB)     Sector: Healthcare  >  Industry: Biotechnology & Drugs
Who's Next in the Biotech Buyout Frenzy?

Oct 13, 2008 12:56 AM GMT
Mikerun
Return Risk
+1.04% MID
Principal

Who's Next in the Biotech Buyout Frenzy?

The biotech industry is rapidly consolidating as big pharma companies put their cash stash to use in deals ranging from well-known large caps all the way down to unknown micro-caps in an effort to bolster their range of marketed products, late stage pipeline candidates, and drug discovery technology platforms.

Genentech (DNA) has rejected Roche's (RHHBY) $89 bid to acquire the remaining 44% of DNA it does not already own as insufficient. I think DNA could easily get $100 per share based on Eli Lilly's (LLY) $70 buyout of ImClone Systems (IMCL), which trumped Erbitux marketing partner Bristol-Myers' (BMY) raised bid of $62 per share. Also, several buyouts in the out-of-favor small and micro-cap biotech space have been announced over the past year with 100%-plus takeover premiums, including under-the-radar names such as:

(1.) SGX Pharma (SGXP) was acquired for $64M cash by Lilly for its cancer drug discovery platform

(2.) Kosan Biosciences (KOSN) was acquired by Bristol-Myers for its cancer drug pipeline

(3.) Barrier Therapeutics (BTRX) was acquired by privately-held Stiefel Labs

(4.) Pfizer's $164M cash buyout of cancer drug developer Coley Pharma (COLY)

(5.) Shionogi (Tokyo: 4507) recently closed its $1.4B cash buyout of Sciele Pharma (SCRX)

My guess as to who may be next is based on the following factors:

(1.) existing big pharma partnerships: Bayer + Onyx Pharma (ONXX)

(2.) high margin orphan drugs: Kuvan – BioMarin (BMRN) & Soliris – Alexion (ALXN)

(3.) revolutionary drug discovery technology platforms: RNAi for Isis Pharma (ISIS) & Alnylam (ALNY)

(4.) a late-stage pipeline + approved biological agents: Biogen (BIIB)


BIIB:  This call was made on 10/13/08 @ $43.98
Rating:   Positive   $43.98 (10/13/08)
Closed:   10/25/2008 @ $41.21 (-6.30% in 12 days)


Comments (2)

Add Comment

Arrow_up
Arrow_down
leonel80   N/A     1 point   commented 438 days ago reply

The most important investment decision is putting money into something with the expectation of profit. More specifically, investment is the commitment of money or capital to the purchase of financial or other assets so as to gain profitable returns in the form of interest, income (dividends), or appreciation (capital gains) of the value of the instrument.

In the case of investment, rather than store the good produced or its money equivalent, the investor chooses to use that good either to create a durable consumer or producer good, or to lend the original saved good to another in exchange for either interest or a share of the profits. In the first case, the individual creates durable consumer goods, hoping the services from the good will make his life better. In the second, the individual becomes an entrepreneur using the resource to produce goods and services for others in the hope of a profitable sale. The third case describes a lender, and the fourth describes an investor in a share of the business. In each case, the consumer obtains a durable asset or investment, and accounts for that asset by recording an equivalent liability. As time passes, and both prices and interest rates change, the value of the asset and liability also change.

Forex & business firms or organisations raise funds from investors in the form of equites,debts(collectively known as the capital structure)and further reinvest it into various investment schemes by carefully analysing the returns in order to meet out their obligations relating to purchase of assets which provides them long term benefits.

Arrow_up
Arrow_down
ozipek   N/A     1 point   commented 412 days ago reply

biber hapı | Maurers | zayıflama | Lw6090 | altın çilek | Ozon Yağı | Red Pepper | fx15 | radian | Tengda | Tengda Zayıflama Hapı | Tengda Kullanımı | Tengda Kullanıcı Yorumları | Tengda Sipariş | Tengda Hakkında | Tengda İçindekiler | Tengda Etkileri | Tengda Yan Etkileri | Maurers | Maurers Kullanımı | Maurers Kullanıcı Yorumları | Maurers Sipariş | Maurers Hakkında | Maurers Zayıflama Hapı | Maurers İçindekiler | Maurers Etkileri | Maurers Yan Etkileri |


Your Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 21.10 +34.36% 531
2 18.14 +36.28% 286
3 17.66 +23.07% 83
4 13.47 +13.37% 69
5 12.13 +132.16% 102


POPULAR STOCKS
Symbol Company Name Sentiment

TODAY'S HEADLINES

TODAY'S TOP PICKS

 
Biogen Idec Inc (BIIB)
   SocialPicks Sentiment:   

   This Quarter's Sentiment:
All:
77.0%
Top:
66.5%




Latest Picks by Mike Havrilla
Symbol SP Sentiment Rating Return Since
AMRN Positive +86.01% 11/29/10
IBB Positive +39.69% 11/22/10
EXAS Positive +35.19% 10/21/10
BIOD Positive -83.37% 10/17/10
LCI N/A Positive -21.73% 10/06/10

View All >
   
Mike Havrilla previously rated BIIB
Positive +193.28% FDA Calendar Updates: Amgen, Bayer, Biogen, Noveko, Peplin, Transdel
07/08/2009
9
Positive -12.22% FDA Decision Calendar: Pain Drug Delays Likely
02/10/2009
9
Positive +29.15% Biogen Reports Another PML Case in Tysabri Patient
10/30/2008
9
Positive +0.00% Biogen Reports Another PML Case in Tysabri Patient
10/29/2008
9
Positive -3.42% Biotech Blues: Four Stocks on Sale with Hope
10/25/2008
9
Positive +0.00% An Even Pfatter Yield at Pfizer
10/12/2008
9
Positive +0.00% Bullish on BIIB ...
10/11/2008
0
Positive -9.49% Clarity on Tysabri Makes Elan and Biogen a Buy
09/06/2008
3





IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch